accountReaction Biology Corporation ("RBC") announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpotSM drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC's methyltransferase screens from 14 to 35 or more.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Reaction Biology Receives NCI Grant Award for Epigenetic Platform
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account